Auspherix To Present Organogold Pipeline At Superbugs & Superdrugs
Stevenage, UK – 20 March 2017 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017.
Chief Scientific Officer Richard Rutter will present on Auspherix’s discovery of a novel class of organogold antibiotics and will focus on antimicrobial profiling, in vitro characterisation and mechanistic insights at 16.10 on Tuesday 21 March. Last month the WHO published its first ever list of antibiotic-resistant "priority pathogens" – a focused list of 12 families of bacteria that pose the greatest threat to human health.
“Being active against Gram negative and Gram positive bacteria, Auspherix’s organogold compounds have shown activity against a number of the 12 pathogens on the WHO list, including all three critical threats,” noted Dr Neil Miller CEO of Auspherix.
SMi’s 19th annual Superbugs & Superdrugs Conference will host an international audience of scientific leaders, funding bodies and drug discovery scientists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
- ENDS -
Notes To Editors
About Auspherix Ltd
Auspherix is an anti-infectives company engaged in the discovery and development of a new class of organogold-based antibiotics for serious and difficult to treat, or potentially life threatening infections.
Its new class of antibiotics demonstrate potent and broad-spectrum activity against both Gram-positive and Gram-negative bacteria including many Gram-negative multi-drug resistant (MDR) strains where there is a global rising unmet medical need and large market potential.
The Company is utilising its proprietary organogold chemistry platform to build a pipeline of novel antibacterials with an initial focus on treating complicated urinary tract infections (cUTI). Auspherix pipeline comprises three structurally distinct, small molecule lead series currently in pre-clinical development.
As a private company, Auspherix is backed by experienced investors including the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations plc (AIM IVO). The Company is located at the Stevenage Bioscience Catalyst facility, UK a world-leading hub for open innovation and centre for fast growing biotech, pharma and medtech businesses.
For further information please visit www.auspherix.com. Follow us on twitter @auspherix and on LinkedIn. Issued for and on behalf of Auspherix by Instinctif Partners.
For more information please contact:
Media Relations - Instinctif Partners
Sue Charles / Gemma Harris
T: +44 (0)20 7457 2020
E: auspherix@instinctif.com
Auspherix
Dr Neil Miller
T: +44 (0)1438 906755
E: neil.miller@auspherix.com
Chief Scientific Officer Richard Rutter will present on Auspherix’s discovery of a novel class of organogold antibiotics and will focus on antimicrobial profiling, in vitro characterisation and mechanistic insights at 16.10 on Tuesday 21 March. Last month the WHO published its first ever list of antibiotic-resistant "priority pathogens" – a focused list of 12 families of bacteria that pose the greatest threat to human health.
“Being active against Gram negative and Gram positive bacteria, Auspherix’s organogold compounds have shown activity against a number of the 12 pathogens on the WHO list, including all three critical threats,” noted Dr Neil Miller CEO of Auspherix.
SMi’s 19th annual Superbugs & Superdrugs Conference will host an international audience of scientific leaders, funding bodies and drug discovery scientists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
- ENDS -
Notes To Editors
About Auspherix Ltd
Auspherix is an anti-infectives company engaged in the discovery and development of a new class of organogold-based antibiotics for serious and difficult to treat, or potentially life threatening infections.
Its new class of antibiotics demonstrate potent and broad-spectrum activity against both Gram-positive and Gram-negative bacteria including many Gram-negative multi-drug resistant (MDR) strains where there is a global rising unmet medical need and large market potential.
The Company is utilising its proprietary organogold chemistry platform to build a pipeline of novel antibacterials with an initial focus on treating complicated urinary tract infections (cUTI). Auspherix pipeline comprises three structurally distinct, small molecule lead series currently in pre-clinical development.
As a private company, Auspherix is backed by experienced investors including the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations plc (AIM IVO). The Company is located at the Stevenage Bioscience Catalyst facility, UK a world-leading hub for open innovation and centre for fast growing biotech, pharma and medtech businesses.
For further information please visit www.auspherix.com. Follow us on twitter @auspherix and on LinkedIn. Issued for and on behalf of Auspherix by Instinctif Partners.
For more information please contact:
Media Relations - Instinctif Partners
Sue Charles / Gemma Harris
T: +44 (0)20 7457 2020
E: auspherix@instinctif.com
Auspherix
Dr Neil Miller
T: +44 (0)1438 906755
E: neil.miller@auspherix.com